Compare Moderna, Inc. (MRNA) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

Rivian Automotive (RIVN) trades at $17.76, up 1.75% on the day, with a neutral technical outlook and bullish moving averages. The company continues to post significant losses, with a net income margin of -63.62% in 2025, though revenue grew to $5.39 billion. Recent news highlights focus on the upcoming R2 vehicle launch and a challenging EV market environment.

Rivian's investment case hinges on successful execution of the R2 launch and path to profitability, but faces substantial risks from cash burn, competition, and macroeconomic pressures. Analyst consensus is a Buy with a $19.22 price target, suggesting moderate upside potential from current levels if operational improvements materialize.